Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    J Histochem Cytochem. 2009 Jan;57(1):7-8. doi: 10.1369/jhc.2008.952820. Epub 2008 Oct 14.

    Commercial antibodies: the good, bad, and really ugly.

    Source

    Biomedicine Institute, University of Copenhagen, Biocenter, Ole Maaloes Vej 5, 2200 Copenhagen N, Denmark. john.couchman@bric.dk

    Abstract

    The range of antibodies available commercially grows ever larger. Perhaps as a consequence, quality control is not always what it could and should be. Investigators must be aware of potential pitfalls and take steps to assure themselves that the specificity of each antibody is as advertised. Additionally, companies should provide the necessary information about the antigen and antibody to investigators, including references, so that the appropriate controls can be included.

    PMID:
    18854593
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2605718
    Free PMC Article

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk